PHENTERMINE GENERICHEALTH, PHENTERMINE GH, PHENTERMINE LAPL (Lupin Australia Pty Limited)

PHENTERMINE GENERICHEALTH, PHENTERMINE GH, PHENTERMINE LAPL (modified release capsule) is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m² or greater. The treatment with PHENTERMINE GENERICHEALTH, PHENTERMINE GH, PHENTERMINE can be initiated in overweight patients with a lower BMI (25 to 29.9 kg/m²), which increases the risk of morbidity from a number of disorders. Secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.